Patients with MDS and AML have been found to produce a variety of inflammatory cytokines (59–63), and these inflammatory mediators have been shown to directly support the growth of stem cells containing SF3B1 mutation, resulting in the development of animal models of MDS (59, 64–67). The gene discussed is SF3B1; the disease is myelodysplastic syndrome.